InvestorsHub Logo
Replies to #17736 on Biotech Values

io_io

10/31/05 9:09 PM

#17744 RE: DewDiligence #17736

"Imitation Naugahide....."

Any other objections to the BLA case, other than that Survival was not an EndPoint ?

(ps: I don't think it was even a Secondary EndPoint, which should reinforce your argument).

Just wondering if you spy any other deceptions.

DewDiligence

03/27/06 9:16 PM

#26332 RE: DewDiligence #17736

DNDN update:

In message #17742, from last October, I said:

>>
Here are some other predictions:

1. DNDN will not in the near future be able to attract a commercialization partner for Provenge on the kinds of terms one would ordinarily expect for a post-phase-3 product in a large medical indication such as prostate cancer.

2. One or more additional senior executives will leave the company before the BLA is approved.

3. DNDN will talk less often about its manufacturing buildout because these plans will be moved to the back burner.

JMHO, FWIW. If I’m wrong, I’ll be the first to admit it.

<<

Five months later, prediction #1 and, especially, prediction #2 look like they were spot-on. Moreover, the DNDN stock price has continued its relentless decline and now sits at a new multi-year low.

Speaking empirically, I think my comments vis-à-vis DNDN have been more reliable than those of one of the other regular posters here.

DewDiligence

04/07/06 4:16 PM

#26923 RE: DewDiligence #17736

DNDN scales back manufacturing plans:

http://www.sec.gov/Archives/edgar/data/1107332/000119312506075610/dex1039.htm

>>
First Amendment
to the Construction Agreement between
The Henderson Corporation and Dendreon Corporation

THIS FIRST AMENDMENT to the Construction Agreement (the “First Amendment”) dated as of April 4, 2006, is entered into by and between Dendreon Corporation, having an office at 3005 First Avenue, Seattle, WA, 98121 (“Owner”) and The Henderson Corporation, having an office at 575 State Hwy. 28, Raritan, NJ, 08869 (“Contractor”).

The scope of work is revised to reduce the size of the New Jersey manufacturing facility from a 48 workstation facility to a 12 workstation facility with appropriate laboratory and support areas.
<<



Referring back to the three predictions I made six months ago in #msg-8310781, it looks like I’m now batting 3 for 3.

DNDN is like a train wreck in slow motion.